Advertisement

Research advances in metabolism 2016

  • Nikolaos Perakakis
    Correspondence
    Corresponding author at: Division of Endocrinology, Beth Israel Deaconess Medical Center, Harvard Medical School, FD-876, 330 Brookline Avenue, Boston, MA 02215. Tel.: +1 617 667 8630; fax: +1 617 667 8634.
    Affiliations
    Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Search for articles by this author
  • Olivia M. Farr
    Affiliations
    Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Search for articles by this author
  • Dario Tuccinardi
    Affiliations
    Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    Search for articles by this author
  • Jagriti Upadhyay
    Affiliations
    Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

    Section of Endocrinology, Boston VA Healthcare System, Harvard Medical School, Boston, MA 02130, USA
    Search for articles by this author
  • Christos S. Mantzoros
    Affiliations
    Division of Endocrinology, Diabetes and Metabolism, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA

    Section of Endocrinology, Boston VA Healthcare System, Harvard Medical School, Boston, MA 02130, USA
    Search for articles by this author
Published:November 06, 2016DOI:https://doi.org/10.1016/j.metabol.2016.11.001
      Metabolic-related research is continuously evolving, since obesity, type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) are the new epidemics of modern societies. Here, we summarize a selection of exceptional experimental and clinical studies published in Metabolism in 2016. We begin with very promising basic research studies and continue with important non-interventional as well as interventional clinical research studies. The aim of this work is to effectively summarize important advances in Metabolism as well as to present directions for future research.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Metabolism - Clinical and Experimental
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Wang H.
        • Taussig M.D.
        • DiPatrizio N.V.
        • Bruce K.
        • Piomelli D.
        • Eckel R.H.
        Obesity development in neuron-specific lipoprotein lipase deficient mice is not responsive to increased dietary fat content or change in fat composition.
        Metabolism. 2016; 65: 987-997
        • Dyall S.C.
        Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA.
        Front Aging Neurosci. 2015; 7: 52
        • Wang H.
        • Astarita G.
        • Taussig M.D.
        • Bharadwaj K.G.
        • DiPatrizio N.V.
        • Nave K.A.
        • et al.
        Deficiency of lipoprotein lipase in neurons modifies the regulation of energy balance and leads to obesity.
        Cell Metab. 2011; 13: 105-113
        • Yasumoto Y.
        • Hashimoto C.
        • Nakao R.
        • Yamazaki H.
        • Hiroyama H.
        • Nemoto T.
        • et al.
        Short-term feeding at the wrong time is sufficient to desynchronize peripheral clocks and induce obesity with hyperphagia, physical inactivity and metabolic disorders in mice.
        Metabolism. 2016; 65: 714-727
        • Dibner C.
        • Schibler U.
        • Albrecht U.
        The mammalian circadian timing system: organization and coordination of central and peripheral clocks.
        Annu Rev Physiol. 2010; 72: 517-549
        • Parsons M.J.
        • Moffitt T.E.
        • Gregory A.M.
        • Goldman-Mellor S.
        • Nolan P.M.
        • Poulton R.
        • et al.
        Social jetlag, obesity and metabolic disorder: investigation in a cohort study.
        Int J Obes (Lond). 2015; 39: 842-848
        • Hatori M.
        • Vollmers C.
        • Zarrinpar A.
        • DiTacchio L.
        • Bushong E.A.
        • Gill S.
        • et al.
        Time-restricted feeding without reducing caloric intake prevents metabolic diseases in mice fed a high-fat diet.
        Cell Metab. 2012; 15: 848-860
        • Li D.J.
        • Fu H.
        • Zhao T.
        • Ni M.
        • Shen F.M.
        Exercise-stimulated FGF23 promotes exercise performance via controlling the excess reactive oxygen species production and enhancing mitochondrial function in skeletal muscle.
        Metabolism. 2016; 65: 747-756
        • Beenken A.
        • Mohammadi M.
        The FGF family: biology, pathophysiology and therapy.
        Nat Rev Drug Discov. 2009; 8: 235-253
        • Hu M.C.
        • Shiizaki K.
        • Kuro-o M.
        • Moe O.W.
        Fibroblast growth factor 23 and klotho: physiology and pathophysiology of an endocrine network of mineral metabolism.
        Annu Rev Physiol. 2013; 75: 503-533
        • Parker B.D.
        • Schurgers L.J.
        • Brandenburg V.M.
        • Christenson R.H.
        • Vermeer C.
        • Ketteler M.
        • et al.
        The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the heart and soul study.
        Ann Intern Med. 2010; 152: 640-648
        • Spichtig D.
        • Zhang H.
        • Mohebbi N.
        • Pavik I.
        • Petzold K.
        • Stange G.
        • et al.
        Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease.
        Kidney Int. 2014; 85: 1340-1350
        • Tsompanidis A.
        • Vafiadaki E.
        • Bluher S.
        • Kalozoumi G.
        • Sanoudou D.
        • Mantzoros C.S.
        Ciliary neurotrophic factor upregulates follistatin and Pak1, causes overexpression of muscle differentiation related genes and downregulation of established atrophy mediators in skeletal muscle.
        Metabolism. 2016; 65: 915-925
        • Bluher S.
        • Moschos S.
        • Bullen Jr., J.
        • Kokkotou E.
        • Maratos-Flier E.
        • Wiegand S.J.
        • et al.
        Ciliary neurotrophic factorAx15 alters energy homeostasis, decreases body weight, and improves metabolic control in diet-induced obese and UCP1-DTA mice.
        Diabetes. 2004; 53: 2787-2796
        • Catalogna M.
        • Fishman S.
        • Halpern Z.
        • Ben-Shlomo S.
        • Nevo U.
        • Ben-Jacob E.
        Regulation of glucose dynamics by noninvasive peripheral electrical stimulation in normal and insulin-resistant rats.
        Metabolism. 2016; 65: 863-873
        • Ishizaki N.
        • Okushi N.
        • Yano T.
        • Yamamura Y.
        Improvement in glucose tolerance as a result of enhanced insulin sensitivity during electroacupuncture in spontaneously diabetic Goto-Kakizaki rats.
        Metabolism. 2009; 58: 1372-1378
        • Chang S.L.
        • Lin K.J.
        • Lin R.T.
        • Hung P.H.
        • Lin J.G.
        • Cheng J.T.
        Enhanced insulin sensitivity using electroacupuncture on bilateral Zusanli acupoints (ST 36) in rats.
        Life Sci. 2006; 79: 967-971
        • Lin R.T.
        • Chen C.Y.
        • Tzeng C.Y.
        • Lee Y.C.
        • Cheng Y.W.
        • Chen Y.I.
        • et al.
        Electroacupuncture improves glucose tolerance through cholinergic nerve and nitric oxide synthase effects in rats.
        Neurosci Lett. 2011; 494: 114-118
        • Hansen J.S.
        • Krintel C.
        • Hernebring M.
        • Haataja T.J.K.
        • de Mare S.
        • et al.
        Perilipin 1 binds to aquaporin 7 in human adipocytes and controls its mobility via protein kinase a mediated phosphorylation.
        Metabolism. 2016; 65: 1731-1742
        • Chen M.
        • Li H.
        • Wang G.
        • Shen X.
        • Zhao S.
        • Su W.
        Atorvastatin prevents advanced glycation end products (AGES)-induced cardiac fibrosis via activating peroxisome proliferator-activated receptor gamma (PPAR-gamma).
        Metabolism. 2016; 65: 441-453
        • Asbun J.
        • Villarreal F.J.
        The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy.
        J Am Coll Cardiol. 2006; 47: 693-700
        • Ihm S.H.
        • Chang K.
        • Kim H.Y.
        • Baek S.H.
        • Youn H.J.
        • Seung K.B.
        • et al.
        Peroxisome proliferator-activated receptor-gamma activation attenuates cardiac fibrosis in type 2 diabetic rats: the effect of rosiglitazone on myocardial expression of receptor for advanced glycation end products and of connective tissue growth factor.
        Basic Res Cardiol. 2010; 105: 399-407
        • Pintana H.
        • Pratchayasakul W.
        • Sa-nguanmoo P.
        • Pongkan W.
        • Tawinvisan R.
        • Chattipakorn N.
        • et al.
        Testosterone deprivation has neither additive nor synergistic effects with obesity on the cognitive impairment in orchiectomized and/or obese male rats.
        Metabolism. 2016; 65: 54-67
        • Janowsky J.S.
        Thinking with your gonads: testosterone and cognition.
        Trends Cogn Sci. 2006; 10: 77-82
        • Morrison C.D.
        • Pistell P.J.
        • Ingram D.K.
        • Johnson W.D.
        • Liu Y.
        • Fernandez-Kim S.O.
        • et al.
        High fat diet increases hippocampal oxidative stress and cognitive impairment in aged mice: implications for decreased NRF2 signaling.
        J Neurochem. 2010; 114: 1581-1589
        • Kampmann K.
        • Ueberberg S.
        • Menge B.A.
        • Breuer T.G.
        • Uhl W.
        • Tannapfel A.
        • et al.
        Abundance and turnover of glp-1 producing l-cells in ileal mucosa are not different in patients with and without type 2 diabetes.
        Metabolism. 2016; 65: 84-91
        • Nauck M.A.
        • Bartels E.
        • Orskov C.
        • Ebert R.
        • Creutzfeldt W.
        Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.
        J Clin Endocrinol Metab. 1993; 76: 912-917
        • Nauck M.
        • Stockmann F.
        • Ebert R.
        • Creutzfeldt W.
        Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.
        Diabetologia. 1986; 29: 46-52
        • Vollmer K.
        • Gardiwal H.
        • Menge B.A.
        • Goetze O.
        • Deacon C.F.
        • Schmidt W.E.
        • et al.
        Hyperglycemia acutely lowers the postprandial excursions of glucagon-like peptide-1 and gastric inhibitory polypeptide in humans.
        J Clin Endocrinol Metab. 2009; 94: 1379-1385
        • Meier J.J.
        • Ritter P.R.
        • Jacob A.
        • Menge B.A.
        • Deacon C.F.
        • Schmidt W.E.
        • et al.
        Impact of exogenous hyperglucagonemia on postprandial concentrations of gastric inhibitory polypeptide and glucagon-like peptide-1 in humans.
        J Clin Endocrinol Metab. 2010; 95: 4061-4065
        • Tanaka M.
        • Matsuo Y.
        • Yamakage H.
        • Masuda S.
        • Terada Y.
        • Muranaka K.
        • et al.
        Differential effects of GLP-1 receptor agonist on foam cell formation in monocytes between non-obese and obese subjects.
        Metabolism. 2016; 65: 1-11
        • Satoh-Asahara N.
        • Sasaki Y.
        • Wada H.
        • Tochiya M.
        • Iguchi A.
        • Nakagawachi R.
        • et al.
        A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients.
        Metabolism. 2013; 62: 347-351
        • Chaudhuri A.
        • Ghanim H.
        • Vora M.
        • Sia C.L.
        • Korzeniewski K.
        • Dhindsa S.
        • et al.
        Exenatide exerts a potent antiinflammatory effect.
        J Clin Endocrinol Metab. 2012; 97: 198-207
        • Galluzzi L.
        • Pietrocola F.
        • Levine B.
        • Kroemer G.
        Metabolic control of autophagy.
        Cell. 2014; 159: 1263-1276
        • Schneider J.L.
        • Cuervo A.M.
        Autophagy and human disease: emerging themes.
        Curr Opin Genet Dev. 2014; 26: 16-23
        • Lee D.S.
        • Lee E.S.
        • Alam M.M.
        • Jang J.H.
        • Lee H.S.
        • Oh H.
        • et al.
        Soluble DPP-4 up-regulates toll-like receptors and augments inflammatory reactions, which are ameliorated by vildagliptin or mannose-6-phosphate.
        Metabolism. 2016; 65: 89-101
        • Gorrell M.D.
        • Gysbers V.
        • McCaughan G.W.
        CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes.
        Scand J Immunol. 2001; 54: 249-264
        • Ohnuma K.
        • Takahashi N.
        • Yamochi T.
        • Hosono O.
        • Dang N.H.
        • Morimoto C.
        Role of CD26/dipeptidyl peptidase IV in human T cell activation and function.
        Front Biosci. 2008; 13: 2299-2310
        • Duke-Cohan J.S.
        • Morimoto C.
        • Rocker J.A.
        • Schlossman S.F.
        A novel form of dipeptidylpeptidase IV found in human serum. Isolation, characterization, and comparison with T lymphocyte membrane dipeptidylpeptidase IV (CD26).
        J Biol Chem. 1995; 270: 14107-14114
        • Lee S.A.
        • Kim Y.R.
        • Yang E.J.
        • Kwon E.J.
        • Kim S.H.
        • Kang S.H.
        • et al.
        CD26/DPP4 levels in peripheral blood and t cells in patients with type 2 diabetes mellitus.
        J Clin Endocrinol Metab. 2013; 98: 2553-2561
        • Lamers D.
        • Famulla S.
        • Wronkowitz N.
        • Hartwig S.
        • Lehr S.
        • Ouwens D.M.
        • et al.
        Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome.
        Diabetes. 2011; 60: 1917-1925
        • Ikushima H.
        • Munakata Y.
        • Ishii T.
        • Iwata S.
        • Terashima M.
        • Tanaka H.
        • et al.
        Internalization of CD26 by mannose 6-phosphate/insulin-like growth factor ii receptor contributes to T cell activation.
        Proc Natl Acad Sci U S A. 2000; 97: 8439-8444
        • Ervinna N.
        • Mita T.
        • Yasunari E.
        • Azuma K.
        • Tanaka R.
        • Fujimura S.
        • et al.
        Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male Apo e-deficient mice.
        Endocrinology. 2013; 154: 1260-1270
        • Ohnuma K.
        • Uchiyama M.
        • Yamochi T.
        • Nishibashi K.
        • Hosono O.
        • Takahashi N.
        • et al.
        Caveolin-1 triggers T-cell activation via CD26 in association with carma1.
        J Biol Chem. 2007; 282: 10117-10131
        • Kimura S.
        • Inoguchi T.
        • Yamasaki T.
        • Yamato M.
        • Ide M.
        • Sonoda N.
        • et al.
        A novel DPP-4 inhibitor teneligliptin scavenges hydroxyl radicals: in vitro study evaluated by electron spin resonance spectroscopy and in vivo study using DPP-4 deficient rats.
        Metabolism. 2016; 65: 138-145
        • Kroller-Schon S.
        • Knorr M.
        • Hausding M.
        • Oelze M.
        • Schuff A.
        • Schell R.
        • et al.
        Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition.
        Cardiovasc Res. 2012; 96: 140-149
        • Matsui T.
        • Nishino Y.
        • Takeuchi M.
        • Yamagishi S.
        Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis.
        Pharmacol Res. 2011; 63: 383-388
        • Maeda S.
        • Matsui T.
        • Yamagishi S.
        Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats.
        Int J Cardiol. 2012; 158: 171-173
        • Kern M.
        • Kloting N.
        • Mark M.
        • Mayoux E.
        • Klein T.
        • Bluher M.
        The SGLT2 inhibitor empagliflozin improves insulin sensitivity in db/db mice both as monotherapy and in combination with linagliptin.
        Metabolism. 2016; 65: 114-123
        • Thomas L.
        • Grempler R.
        • Eckhardt M.
        • Himmelsbach F.
        • Sauer A.
        • Klein T.
        • et al.
        Long-term treatment with empagliflozin, a novel, potent and selective SGLT-2 inhibitor, improves glycaemic control and features of metabolic syndrome in diabetic rats.
        Diabetes Obes Metab. 2012; 14: 94-96
        • Luippold G.
        • Klein T.
        • Mark M.
        • Grempler R.
        Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus.
        Diabetes Obes Metab. 2012; 14: 601-607
        • Deacon C.F.
        • Holst J.J.
        Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.
        Expert Opin Investig Drugs. 2010; 19: 133-140
        • Thomas L.
        • Eckhardt M.
        • Langkopf E.
        • Tadayyon M.
        • Himmelsbach F.
        • Mark M.
        (r)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylm ethyl)-3,7-dihydro-purine-2,6-dione (bi 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors.
        J Pharmacol Exp Ther. 2008; 325: 175-182
        • Kern M.
        • Kloting N.
        • Niessen H.G.
        • Thomas L.
        • Stiller D.
        • Mark M.
        • et al.
        Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity.
        PLoS One. 2012; 7: e38744
        • Rhee E.J.
        • Park S.E.
        • Chang Y.
        • Ryu S.
        • Lee W.Y.
        Baseline glycemic status and mortality in 241,499 Korean metropolitan subjects: a Kangbuk Samsung health study.
        Metabolism. 2016; 65: 68-77
        • Tabara Y.
        • Takahashi Y.
        • Setoh K.
        • Kawaguchi T.
        • Gotoh N.
        • Terao C.
        • et al.
        Synergistic association of elevated serum free fatty acid and glucose levels with large arterial stiffness in a general population: the Nagahama study.
        Metabolism. 2016; 65: 66-72
        • Kim J.A.
        • Montagnani M.
        • Koh K.K.
        • Quon M.J.
        Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms.
        Circulation. 2006; 113: 1888-1904
        • Gasbarrino K.
        • Gorgui J.
        • Nauche B.
        • Cote R.
        • Daskalopoulou S.S.
        Circulating adiponectin and carotid intima–media thickness: a systematic review and meta-analysis.
        Metabolism. 2016; 65: 968-986
        • Ebrahimi-Mamaeghani M.
        • Mohammadi S.
        • Arefhosseini S.R.
        • Fallah P.
        • Bazi Z.
        Adiponectin as a potential biomarker of vascular disease.
        Vasc Health Risk Manag. 2015; 11: 55-70
        • Ohashi K.
        • Ouchi N.
        • Matsuzawa Y.
        Anti-inflammatory and anti-atherogenic properties of adiponectin.
        Biochimie. 2012; 94: 2137-2142
        • Weyer C.
        • Funahashi T.
        • Tanaka S.
        • Hotta K.
        • Matsuzawa Y.
        • Pratley R.E.
        • et al.
        Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.
        J Clin Endocrinol Metab. 2001; 86: 1930-1935
        • Gardener H.
        • Sjoberg C.
        • Crisby M.
        • Goldberg R.
        • Mendez A.
        • Wright C.B.
        • et al.
        Adiponectin and carotid intima–media thickness in the northern Manhattan study.
        Stroke. 2012; 43: 1123-1125
        • Liu J.
        • Wang F.
        • Cha Y.
        • Chen Z.P.
        • Ding H.Y.
        Adiponectin levels in non-obese first-degree relatives of type 2 diabetes patients and non-diabetic subjects: a 5-year follow-up study.
        J Int Med Res. 2010; 38: 792-802
        • Anastasilakis A.D.
        • Polyzos S.A.
        • Skouvaklidou E.C.
        • Kynigopoulos G.
        • Saridakis Z.G.
        • Apostolou A.
        • et al.
        Circulating follistatin displays a day-night rhythm and is associated with muscle mass and circulating leptin levels in healthy, young humans.
        Metabolism. 2016; 65: 1459-1465
        • Bilezikjian L.M.
        • Blount A.L.
        • Leal A.M.
        • Donaldson C.J.
        • Fischer W.H.
        • Vale W.W.
        Autocrine/paracrine regulation of pituitary function by activin, inhibin and follistatin.
        Mol Cell Endocrinol. 2004; 225: 29-36
        • Hansen J.
        • Brandt C.
        • Nielsen A.R.
        • Hojman P.
        • Whitham M.
        • Febbraio M.A.
        • et al.
        Exercise induces a marked increase in plasma follistatin: evidence that follistatin is a contraction-induced hepatokine.
        Endocrinology. 2011; 152: 164-171
        • Vamvini M.T.
        • Aronis K.N.
        • Chamberland J.P.
        • Mantzoros C.S.
        Energy deprivation alters in a leptin- and cortisol-independent manner circulating levels of activin A and follistatin but not myostatin in healthy males.
        J Clin Endocrinol Metab. 2011; 96: 3416-3423
        • Hansen J.
        • Rinnov A.
        • Krogh-Madsen R.
        • Fischer C.P.
        • Andreasen A.S.
        • Berg R.M.
        • et al.
        Plasma follistatin is elevated in patients with type 2 diabetes: relationship to hyperglycemia, hyperinsulinemia, and systemic low-grade inflammation.
        Diabetes Metab Res Rev. 2013; 29: 463-472
        • Yndestad A.
        • Haukeland J.W.
        • Dahl T.B.
        • Bjoro K.
        • Gladhaug I.P.
        • Berge C.
        • et al.
        A complex role of activin a in non-alcoholic fatty liver disease.
        Am J Gastroenterol. 2009; 104: 2196-2205
        • Teede H.
        • Ng S.
        • Hedger M.
        • Moran L.
        Follistatin and activins in polycystic ovary syndrome: relationship to metabolic and hormonal markers.
        Metabolism. 2013; 62: 1394-1400
        • Bogl L.H.
        • Kaye S.M.
        • Ramo J.T.
        • Kangas A.J.
        • Soininen P.
        • Hakkarainen A.
        • et al.
        Abdominal obesity and circulating metabolites: a twin study approach.
        Metabolism. 2016; 65: 111-121
        • Brachs M.
        • Wiegand S.
        • Leupelt V.
        • Ernert A.
        • Kintscher U.
        Jumpertz von Schwarzenberg R, et al. ANP system activity predicts variability of fat mass reduction and insulin sensitivity during weight loss.
        Metabolism. 2016; 65: 935-943
        • Birkenfeld A.L.
        • Boschmann M.
        • Moro C.
        • Adams F.
        • Heusser K.
        • Tank J.
        • et al.
        Beta-adrenergic and atrial natriuretic peptide interactions on human cardiovascular and metabolic regulation.
        J Clin Endocrinol Metab. 2006; 91: 5069-5075
        • Schlueter N.
        • de Sterke A.
        • Willmes D.M.
        • Spranger J.
        • Jordan J.
        • Birkenfeld A.L.
        Metabolic actions of natriuretic peptides and therapeutic potential in the metabolic syndrome.
        Pharmacol Ther. 2014; 144: 12-27
        • Yu T.Y.
        • Jee J.H.
        • Bae J.C.
        • Jin S.M.
        • Baek J.H.
        • Lee M.K.
        • et al.
        Serum uric acid: a strong and independent predictor of metabolic syndrome after adjusting for body composition.
        Metabolism. 2016; 65: 432-440
        • Bancks M.P.
        • Bielinski S.J.
        • Decker P.A.
        • Hanson N.Q.
        • Larson N.B.
        • Sicotte H.
        • et al.
        Circulating level of hepatocyte growth factor predicts incidence of type 2 diabetes mellitus: the Multi-Ethnic Study of Atherosclerosis (MESA).
        Metabolism. 2016; 65: 64-72
        • Li J.J.
        • Wittert G.A.
        • Vincent A.
        • Atlantis E.
        • Shi Z.
        • Appleton S.L.
        • et al.
        Muscle grip strength predicts incident type 2 diabetes: population-based cohort study.
        Metabolism. 2016; 65: 883-892
        • Moon S.S.
        Low skeletal muscle mass is associated with insulin resistance, diabetes, and metabolic syndrome in the Korean population: the Korea National Health And Nutrition Examination Survey (KNHANES) 2009–2010.
        Endocr J. 2014; 61: 61-70
        • Park S.W.
        • Goodpaster B.H.
        • Strotmeyer E.S.
        • de Rekeneire N.
        • Harris T.B.
        • Schwartz A.V.
        • et al.
        Decreased muscle strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study.
        Diabetes. 2006; 55: 1813-1818
        • Ding E.L.
        • Song Y.
        • Malik V.S.
        • Liu S.
        Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis.
        JAMA. 2006; 295: 1288-1299
        • Karajamaki A.J.
        • Bloigu R.
        • Kauma H.
        • Kesaniemi Y.A.
        • Koivurova O.P.
        • Perkiomaki J.
        • et al.
        Non-alcoholic fatty liver disease with and without metabolic syndrome: different long-term outcomes.
        Metabolism. 2016;
        • Walle P.
        • Takkunen M.
        • Mannisto V.
        • Vaittinen M.
        • Lankinen M.
        • Karja V.
        • et al.
        Fatty acid metabolism is altered in non-alcoholic steatohepatitis independent of obesity.
        Metabolism. 2016; 65: 655-666
        • Polyzos S.A.
        • Kountouras J.
        • Anastasilakis A.D.
        • Triantafyllou G.
        • Mantzoros C.S.
        Activin A and follistatin in patients with nonalcoholic fatty liver disease.
        Metabolism. 2016; 65: 1550-1558
        • Niu Y.
        • Zhang W.
        • Yang Z.
        • Li X.
        • Fang W.
        • Zhang H.
        • et al.
        Plasma osteoprotegerin levels are inversely associated with nonalcoholic fatty liver disease in patients with type 2 diabetes: a case–control study in China.
        Metabolism. 2016; 65: 475-481
        • Ter Horst K.W.
        • Gilijamse P.W.
        • Ackermans M.T.
        • Soeters M.R.
        • Nieuwdorp M.
        • Romijn J.A.
        • et al.
        Impaired insulin action in the liver, but not in adipose tissue or muscle, is a distinct metabolic feature of impaired fasting glucose in obese humans.
        Metabolism. 2016; 65: 757-763
        • Rizza R.A.
        Pathogenesis of fasting and postprandial hyperglycemia in type 2 diabetes: implications for therapy.
        Diabetes. 2010; 59: 2697-2707
        • Jiang Z.G.
        • de Boer I.H.
        • Mackey R.H.
        • Jensen M.K.
        • Lai M.
        • Robson S.C.
        • et al.
        Associations of insulin resistance, inflammation and liver synthetic function with very low-density lipoprotein: the cardiovascular health study.
        Metabolism. 2016; 65: 92-99
        • Mackey R.H.
        • Mora S.
        • Bertoni A.G.
        • Wassel C.L.
        • Carnethon M.R.
        • Sibley C.T.
        • et al.
        Lipoprotein particles and incident type 2 diabetes in the Multi-Ethnic Study of Atherosclerosis.
        Diabetes Care. 2015; 38: 628-636
        • Charlton M.
        • Sreekumar R.
        • Rasmussen D.
        • Lindor K.
        • Nair K.S.
        Apolipoprotein synthesis in nonalcoholic steatohepatitis.
        Hepatology. 2002; 35: 898-904
        • Cicognani C.
        • Malavolti M.
        • Morselli-Labate A.M.
        • Zamboni L.
        • Sama C.
        • Barbara L.
        Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis.
        Arch Intern Med. 1997; 157: 792-796
        • Vaurs C.
        • Brun J.F.
        • Bertrand M.
        • Burcelin R.
        • du Rieu M.C.
        • Anduze Y.
        • et al.
        Post-prandial hypoglycemia results from a non-glucose-dependent inappropriate insulin secretion in Roux-en-Y gastric bypassed patients.
        Metabolism. 2016; 65: 18-26
        • Lips M.A.
        • van Klinken J.B.
        • Pijl H.
        • Janssen I.
        Willems van Dijk K, Koning F, et al. weight loss induced by very low calorie diet is associated with a more beneficial systemic inflammatory profile than by Roux-en-Y gastric bypass.
        Metabolism. 2016; 65: 1614-1620
        • Lebkowska A.
        • Adamska A.
        • Karczewska-Kupczewska M.
        • Nikolajuk A.
        • Otziomek E.
        • Milewski R.
        • et al.
        Serum anti-Mullerian hormone concentration in women with polycystic ovary syndrome and type 1 diabetes mellitus.
        Metabolism. 2016; 65: 804-811
        • Escobar-Morreale H.F.
        • Roldan B.
        • Barrio R.
        • Alonso M.
        • Sancho J.
        • de la Calle H.
        • et al.
        High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus.
        J Clin Endocrinol Metab. 2000; 85: 4182-4187
        • Codner E.
        • Soto N.
        • Lopez P.
        • Trejo L.
        • Avila A.
        • Eyzaguirre F.C.
        • et al.
        Diagnostic criteria for polycystic ovary syndrome and ovarian morphology in women with type 1 diabetes mellitus.
        J Clin Endocrinol Metab. 2006; 91: 2250-2256
        • Amato M.C.
        • Guarnotta V.
        • Ciresi A.
        • Modica R.
        • Panto F.
        • Giordano C.
        No phenotypic differences for polycystic ovary syndrome (PCOS) between women with and without type 1 diabetes mellitus.
        J Clin Endocrinol Metab. 2014; 99: 203-211
        • Fulghesu A.M.
        • Villa P.
        • Pavone V.
        • Guido M.
        • Apa R.
        • Caruso A.
        • et al.
        The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome.
        J Clin Endocrinol Metab. 1997; 82: 644-648
        • Poretsky L.
        • Grigorescu F.
        • Seibel M.
        • Moses A.C.
        • Flier J.S.
        Distribution and characterization of insulin and insulin-like growth factor i receptors in normal human ovary.
        J Clin Endocrinol Metab. 1985; 61: 728-734
        • Farr O.M.
        • Tsoukas M.A.
        • Triantafyllou G.
        • Dincer F.
        • Filippaios A.
        • Ko B.J.
        • et al.
        Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: a randomized, placebo-controlled, crossover study.
        Metabolism. 2016; 65: 945-953
        • Romu T.
        • Vavruch C.
        • Dahlqvist-Leinhard O.
        • Tallberg J.
        • Dahlstrom N.
        • Persson A.
        • et al.
        A randomized trial of cold-exposure on energy expenditure and supraclavicular brown adipose tissue volume in humans.
        Metabolism. 2016; 65: 926-934
        • Karl J.P.
        • Smith T.J.
        • Wilson M.A.
        • Bukhari A.S.
        • Pasiakos S.M.
        • McClung H.L.
        • et al.
        Altered metabolic homeostasis is associated with appetite regulation during and following 48-h of severe energy deprivation in adults.
        Metabolism. 2016; 65: 416-427
        • Thackray A.E.
        • Barrett L.A.
        • Tolfrey K.
        Energy replacement diminishes the effect of exercise on postprandial lipemia in boys.
        Metabolism. 2016; 65: 496-506
        • Tsuchiya Y.
        • Ijichi T.
        • Goto K.
        Effect of sprint training on resting serum irisin concentration — sprint training once daily vs. twice every other day.
        Metabolism. 2016; 65: 492-495
        • Bostrom P.
        • Wu J.
        • Jedrychowski M.P.
        • Korde A.
        • Ye L.
        • Lo J.C.
        • et al.
        A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis.
        Nature. 2012; 481: 463-468
        • Polyzos S.A.
        • Kountouras J.
        • Anastasilakis A.D.
        • Geladari E.V.
        • Mantzoros C.S.
        Irisin in patients with nonalcoholic fatty liver disease.
        Metabolism. 2014; 63: 207-217
        • Bostrom P.A.
        • Fernandez-Real J.M.
        • Mantzoros C.
        Irisin in humans: recent advances and questions for future research.
        Metabolism. 2014; 63: 178-180
        • Huh J.Y.
        • Mougios V.
        • Kabasakalis A.
        • Fatouros I.
        • Siopi A.
        • Douroudos I.I.
        • et al.
        Exercise-induced irisin secretion is independent of age or fitness level and increased irisin may directly modulate muscle metabolism through AMPK activation.
        J Clin Endocrinol Metab. 2014; 99: E2154-E2161
        • Huh J.Y.
        • Mougios V.
        • Skraparlis A.
        • Kabasakalis A.
        • Mantzoros C.S.
        Irisin in response to acute and chronic whole-body vibration exercise in humans.
        Metabolism. 2014; 63: 918-921
        • Polyzos S.A.
        • Mantzoros C.S.
        An update on the validity of irisin assays and the link between irisin and hepatic metabolism.
        Metabolism. 2015; 64: 937-942
        • Goldberg R.B.
        • Temprosa M.
        • Mele L.
        • Orchard T.
        • Mather K.
        • Bray G.
        • et al.
        Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the diabetes prevention program.
        Metabolism. 2016; 65: 764-775
        • Sahebkar A.
        • Reiner Z.
        • Simental-Mendia L.E.
        • Ferretti G.
        • Cicero A.F.
        Effect of extended-release niacin on plasma lipoprotein(a) levels: a systematic review and meta-analysis of randomized placebo-controlled trials.
        Metabolism. 2016; 65: 1664-1678